Aprea Therapeutics (APRE) Q3 2025 earnings summary

Executive summary

• Focused on precision oncology with lead programs APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor), both in early clinical development and showing promising early efficacy in heavily pretreated cancer patients.

• APR-1051 Phase 1 dose escalation ongoing, with data expected in Q1 2026; 3 of 4 patients at 100 mg achieved stable disease and safety profile is manageable.

• ATRN-119 monotherapy enrollment paused after enrolling 43 patients to explore combination strategies; recommended Phase 2 dose set at 1,100 mg.

• Pipeline includes preclinical DDR-targeting programs; no commercial products or product revenue expected in the near term.

• Posters on APR-1051 and ATRN-119 presented at a major international oncology conference in October 2025.

Financial highlights

• Cash and cash equivalents at September 30, 2025: $13.7 million, down from $22.8 million at December 31, 2024.

• Net loss for Q3 2025: $3.0 million ($0.47 per share), improved from $3.8 million ($0.64 per share) in Q3 2024.

• Net loss for the nine months ended September 30, 2025: $10.1 million, similar to the prior year period.

• R&D expenses decreased to $1.6 million in Q3 2025 from $2.8 million in Q3 2024; for the nine months ended September 30, 2025, R&D expenses were $6.0 million.

• G&A expenses for Q3 2025 were $1.5 million, slightly down from $1.6 million in Q3 2024; for the nine months ended September 30, 2025: $4.8 million, down from $5.4 million year-over-year.

Outlook and guidance

• Cash position expected to fund operations and capital expenditures into Q4 2026, but substantial doubt exists about ability to continue as a going concern without additional funding.

• Actively seeking additional funding; may need to reduce expenditures or curtail development if financing is not secured.

• Anticipates value-creating clinical catalysts in 2026, including potential combination studies for both lead assets.